Equity for our community: today and tomorrow

A petition demanding Down syndrome equity in access to new Alzheimer's therapies

check
I'm ready to signI'm ready to sign
Latest NewsLatest News
What's being done?What's being done?

The Down syndrome community demands equal access to drug therapies that could change our lives.

The Down syndrome community demands equal access to clinical trials, drug therapies, and diagnostics that could change our lives.

I believe that people with Down syndrome deserve equal access to, and insurance coverage for, life-changing drugs and critical diagnostic tests.

The entrenched policies we change today will improve healthcare infrastructure and make access to treatment more equitable for people with Down syndrome in the long term.

In signing this petition, I add my name to the thousands of people who care about the health and well-being of people with Down syndrome.

Today, our fight is focused on urgent inequities around new Alzheimer’s disease therapies and diagnostic tests.

In bringing attention to the issue of Down syndrome equity now, our community is paving the way for access to future breakthrough treatments for other diseases and conditions. The entrenched policies we change today will improve healthcare infrastructure and make diagnoses and access to treatments more equitable for people with Down syndrome in the long term.

Learn more about the need for policy changes in order for people with Down syndrome to have access to life-changing treatments.

5115 ManinDQUniform Print
A young man with Down syndrome and his family sitting on a couch at home

LuMind IDSC invites all who are concerned about this ongoing injustice to sign the petition via this form and add your name to the overdue demand for equity for the Down syndrome community. Thank you!

lumindidsc full logo highres jpeg

Our Petition

— I am a person with Down syndrome
— I love someone with Down syndrome
— I care about the Down syndrome community…

and I believe that people with Down syndrome deserve equal access to and insurance coverage for life-changing drugs and critical diagnostic tests.

1D7A3883

Our community demands

Our community demands

    • From the pharmaceutical industry: Take immediate steps to launch key safety trials in the Down syndrome population.
    • From diagnostic companies: Test blood diagnostics for Alzheimer’s disease in the Down syndrome population.
    • From state, federal, and private insurers: Immediately adopt the proposed Down syndrome-focused prior authorization and equivalency criteria and clear the procedural barriers that currently prevent doctors from prescribing new drugs to people with Down syndrome.
    • From the federal agencies responsible for regulatory oversight: Explore with the community and relevant stakeholders the best way to include people with Down syndrome in Alzheimer’s clinical trials and conclusively clarify a realistic regulatory approval path for new Alzheimer’s drugs for our population.
Fill out my online form.

In submitting this form, I understand that I am sharing my contact information with LuMind IDSC, a 501(c)(3) nonprofit organization dedicated to accelerating Down syndrome research and supporting families with key resources.  LuMind IDSC will not share your information with external partners.